¿Æ¼¼:Ó¢¹úµÄ»ùÒò¼ôµ¶½«¿ª·¢ÐÂÒ©
British pharmaceutical giant AstraZeneca has announced a research programme to develop a new generation of medicines to treat the genetic causes of many debilitating diseases, such as diabetes, heart disease and many cancers.
Ó¢¹úÖÆÒ©¾ÞÍ·°¢Ë¹Àû¿µÖÆÒ©ÈÕǰÐû²¼Ò»ÏîÑо¿¼Æ»®£¬¿ª·¢ÐÂÒ»´úÒ©ÎÖÎÁÆÐí¶àÒòÒÅ´«ÒòËØÒýÆðµÄʹÈËË¥ÈõµÄ¼²²¡£¬ÀýÈçÌÇÄò²¡¡¢ÐÄÔಡºÍ²»ÉÙ°©Ö¢¡£
AstraZeneca said it plans to make use of so-called CRISPR genome-editing technology for key therapeutic areas including oncology. The technology enables researchers to “edit” the genes of certain cells relatively quickly and accurately.
°¢Ë¹Àû¿µ³Æ£¬Æä¼Æ»®ÊÇÔÚ°üÀ¨Ö×ÁöѧµÄÖØÒªÖÎÁÆÁìÓòÀûÓñ»³Æ×÷CRISPRµÄ“»ùÒò¼ôµ¶”¼¼Êõ¡£“»ùÒò¼ôµ¶”¼¼ÊõʹµÃÑо¿ÈËÔ±¿ÉÒÔÏà¶Ô¿ì¶ø×¼µØ“±à¼”һЩϸ°ûµÄ»ùÒò¡£

Some companies are using gene-editing techniques to change the plant's existing DNA rather than insert foreign genes.
һЩ¹«Ë¾ÕýʹÓÓ»ùÒò¼ôµ¶”¼¼ÊõÀ´¸Ä±äÖ²ÎïÏÖÔÚµÄDNA£¬¶ø²»ÊDzåÈëÍâÀ´»ùÒò¡£